Taxane-Platin-Resistant Lung Cancers Co-develop Hypersensitivity to JumonjiC Demethylase Inhibitors.

[1]  Shawn M. Gillespie,et al.  Adaptive Chromatin Remodeling Drives Glioblastoma Stem Cell Plasticity and Drug Tolerance. , 2017, Cell stem cell.

[2]  P. Trojer,et al.  An inhibitor of KDM5 demethylases reduces survival of drug-tolerant cancer cells. , 2016, Nature chemical biology.

[3]  J. O’Leary,et al.  Carboplatin and taxol resistance develops more rapidly in functional BRCA1 compared to dysfunctional BRCA1 ovarian cancer cells. , 2015, Experimental cell research.

[4]  R. Neve,et al.  AXL inhibition sensitizes mesenchymal cancer cells to antimitotic drugs. , 2014, Cancer research.

[5]  Christopher J. Ott,et al.  An epigenetic mechanism of resistance to targeted therapy in T cell acute lymphoblastic leukemia , 2014, Nature Genetics.

[6]  Barbara Mair,et al.  Exploiting epigenetic vulnerabilities for cancer therapeutics. , 2014, Trends in pharmacological sciences.

[7]  S. Peña-Llopis,et al.  A small molecule modulates Jumonji histone demethylase activity and selectively inhibits cancer growth , 2013, Nature Communications.

[8]  P. Gimotty,et al.  Overcoming intrinsic multidrug resistance in melanoma by blocking the mitochondrial respiratory chain of slow-cycling JARID1B(high) cells. , 2013, Cancer cell.

[9]  Christopher J. Schofield,et al.  A selective jumonji H3K27 demethylase inhibitor modulates the proinflammatory macrophage response , 2012, Nature.

[10]  Ji-Young Kim,et al.  KDM3B Is the H3K9 Demethylase Involved in Transcriptional Activation of lmo2 in Leukemia , 2012, Molecular and Cellular Biology.

[11]  G. Almouzni,et al.  The double face of the histone variant H3.3 , 2011, Cell Research.

[12]  Ben S. Wittner,et al.  A Chromatin-Mediated Reversible Drug-Tolerant State in Cancer Cell Subpopulations , 2010, Cell.

[13]  Johan Vansteenkiste,et al.  Phase III study comparing cisplatin plus gemcitabine with cisplatin plus pemetrexed in chemotherapy-naive patients with advanced-stage non-small-cell lung cancer. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[14]  T. Mikkelsen,et al.  Genome-scale DNA methylation maps of pluripotent and differentiated cells , 2008, Nature.

[15]  A. Regev,et al.  An embryonic stem cell–like gene expression signature in poorly differentiated aggressive human tumors , 2008, Nature Genetics.

[16]  Yang Xie,et al.  Enhanced identification and biological validation of differential gene expression via Illumina whole-genome expression arrays through the use of the model-based background correction methodology , 2008, Nucleic acids research.

[17]  J. Luketich,et al.  Chemotherapy resistance and oncogene expression in non-small cell lung cancer. , 2007, The Journal of thoracic and cardiovascular surgery.

[18]  M. Gottesman,et al.  Targeting multidrug resistance in cancer , 2006, Nature Reviews Drug Discovery.

[19]  Pablo Tamayo,et al.  Gene set enrichment analysis: A knowledge-based approach for interpreting genome-wide expression profiles , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[20]  P. Pelicci,et al.  dapk1, encoding an activator of a p19ARF-p53-mediated apoptotic checkpoint, is a transcription target of p53 , 2005, Oncogene.

[21]  Diane D. Liu,et al.  A retrospective analysis of the outcome of patients who have received two prior chemotherapy regimens including platinum and docetaxel for recurrent non-small-cell lung cancer. , 2003, Lung cancer.

[22]  M. Kris,et al.  Long-term results of combined-modality therapy in resectable non-small-cell lung cancer. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[23]  David Harrington,et al.  Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer. , 2002, The New England journal of medicine.

[24]  M. Gottesman,et al.  Multidrug resistance in cancer: role of ATP–dependent transporters , 2002, Nature Reviews Cancer.

[25]  R. Arceci,et al.  Clinical relevance of transmembrane drug efflux as a mechanism of multidrug resistance. , 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[26]  J. Lemontt,et al.  Increased mdr gene expression and decreased drug accumulation in multidrug-resistant human melanoma cells. , 1988, Cancer research.

[27]  I. Pastan,et al.  Isolation of human mdr DNA sequences amplified in multidrug-resistant KB carcinoma cells. , 1986, Proceedings of the National Academy of Sciences of the United States of America.